Man Group
JNCE

Man Group’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Man Group’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-16,090
Closed -$80K – 1961
2019
Q2 		$80K Sell
16,090
-3,361
-17% -$17.8K ﹤0.01% 1843
2019
Q1 		$121K Buy
+19,451
New +$94K ﹤0.01% 1906
2018
Q4 		– Sell
-199,819
Closed -$1.3M – 2172
2018
Q3 		$1.3M Buy
+199,819
New +$1.49M ﹤0.01% 1563

Other funds holding JNCE

TGI
TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Man Group's JNCE Position: Q3 2019 in Review

Man Group sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q3 2019, closing a stake of 16,090 shares — an estimated $80K sold.

Man Group first reported a position in JNCE in Q3 2018 and held it in 3 quarters. The position peaked at $1.3M in Q3 2018. 77 funds tracked by Wall St. Rank hold JNCE as of Q3 2019.

  • Man Group reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q3 2019 after selling out during the quarter.
  • Man Group sold 16,090 Jounce Therapeutics, Inc. Common Stock shares in Q3 2019, an estimated $80K.
  • Man Group first reported a position in Jounce Therapeutics, Inc. Common Stock in Q3 2018 and held it in 3 quarters.
  • Man Group's Jounce Therapeutics, Inc. Common Stock position peaked at $1.3M in Q3 2018.
  • 77 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q3 2019.

Based on Man Group's 13F filing for Q3 2019, filed 14 Nov 2019.